提尔泽帕提德与瘦素在减肥和恢复新陈代谢平衡方面的协同作用在饮食诱导的肥胖模型中
bioRxiv : the preprint server for biology
|January 9, 2026
概括
结合蒂尔泽帕提德 (TZP) 和瘦素,为肥胖管理提供了一种新的策略. 这种组合可以增强体重减轻,提高胰岛素敏感性,并通过敏感化勒丁信号来提高能量消耗.
科学领域:
- 代谢性疾病研究研究.
- 神经内分泌学神经内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘦素耐药性是有效的抗肥胖治疗的重要障碍.
- 蒂尔泽帕提德 (TZP) 是一种双重GLP-1R/GIPR激动剂,在肥胖管理中显示出潜力.
- 起始时的瘦素水平与人类的TZP减肥有效性相关.
研究的目的:
- 为了研究结合蒂尔泽帕提德和瘦素用于治疗肥胖症的协同效应.
- 阐明TZP介导的瘦素敏感化的潜在机制.
主要方法:
- 使用了饮食诱导肥胖 (DIO) 的小鼠模型.
- 施用了提尔泽帕提德和莱普丁 (TZP+Lep) 的联合治疗.
- 在下丘脑神经元中进行了代谢分析,基因表达分析和电生理学记录.
主要成果:
- 在DIO小鼠中,TZP+Lep协同促进了显著的体重减轻.
- 组合疗法改善了肝脏的胰岛素敏感性,并在棕色脂肪组织中调高了发热基因表达.
- 在POMC和GLP-1R神经元中,TZP使瘦素信号敏感,增加了POMC神经元的发射.
结论:
- 结合蒂尔泽帕提德和丁是一种有前途的治疗方法,可以提高肥胖症的减肥和代谢平衡.
- 蒂尔泽帕提德对勒丁信号传递的敏感化能力是驱动协同效应的关键机制.
- 这种组合疗法需要进一步研究,以便在治疗肥胖症方面获得临床应用.
相关概念视频
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K


